CD44 and cancer: The contrasting results observed in Du145 and LAPC9 models with respect to the tumorigenicity of CD44+α2β1+ cells suggest that the ability of combinatorial marker-sorting strategy to further enrich CSCs over single marker strategies is dependent on the cancer model analyzed.